-
Je něco špatně v tomto záznamu ?
Could piracetam potentiate behavioural effects of psychostimulants?
K. Slais, A. Machalova, L. Landa, D. Vrskova, A. Sulcova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- amfetaminy aplikace a dávkování MeSH
- chování zvířat účinky léků fyziologie MeSH
- kombinovaná farmakoterapie MeSH
- myši MeSH
- neuroprotektivní látky aplikace a dávkování MeSH
- piracetam aplikace a dávkování MeSH
- stimulanty centrálního nervového systému aplikace a dávkování MeSH
- synergismus léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Press and internet reports mention abuse of nootropic drug piracetam (PIR) in combination with psychostimulants methamphetamine (MET) or 4-methylenedioxymethamphetamine (MDMA). These combinations are believed to produce more profound desirable effects, while decreasing hangover. However, there is a lack of valid experimental studies on such drug-drug interactions in the scientific literature available. Our hypothesis proposes that a functional interaction exists between PIR and amphetamine psychostimulants (MET and MDMA) which can potentiate psychostimulant behavioural effects. Our hypothesis is supported by the results of our pilot experiment testing acute effects of drugs given to mice intraperitoneally (Vehicle, n=12; MET 2.5mg/kg, n=10; MDMA 2.5mg/kg, n=11; PIR 300 mg/kg, n=12; PIR+MET, n=12; PIR+MDMA, n=11) in the Open Field Test (Actitrack, Panlab, Spain). PIR given alone caused no significant changes in mouse locomotor/exploratory behaviour, whereas the same dose combined with either MET or MDMA significantly enhanced their stimulatory effects. Different possible neurobiological mechanism underlying drug-drug interaction of PIR with MET or MDMA are discussed, as modulation of dopaminergic, glutamatergic or cholinergic brain systems. However, the interaction with membrane phospholipids seems as the most plausible mechanism explaining PIR action on activities of neurotransmitter systems. Despite that our behavioural experiment cannot serve for explanation of the pharmacological mechanisms of these functional interactions, it shows that PIR effects can increase behavioural stimulation of amphetamine drugs. Thus, the reported combining of PIR with MET or MDMA by human abusers is not perhaps a coincidental phenomenon and may be based on existing PIR potential to intensify acute psychostimulant effects of these drugs of abuse.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000802
- 003
- CZ-PrNML
- 005
- 20130110114232.0
- 007
- ta
- 008
- 130108s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.mehy.2012.04.041 $2 doi
- 035 __
- $a (PubMed)22607774
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Slais, Karel $u CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. kslais@med.muni.cz
- 245 10
- $a Could piracetam potentiate behavioural effects of psychostimulants? / $c K. Slais, A. Machalova, L. Landa, D. Vrskova, A. Sulcova,
- 520 9_
- $a Press and internet reports mention abuse of nootropic drug piracetam (PIR) in combination with psychostimulants methamphetamine (MET) or 4-methylenedioxymethamphetamine (MDMA). These combinations are believed to produce more profound desirable effects, while decreasing hangover. However, there is a lack of valid experimental studies on such drug-drug interactions in the scientific literature available. Our hypothesis proposes that a functional interaction exists between PIR and amphetamine psychostimulants (MET and MDMA) which can potentiate psychostimulant behavioural effects. Our hypothesis is supported by the results of our pilot experiment testing acute effects of drugs given to mice intraperitoneally (Vehicle, n=12; MET 2.5mg/kg, n=10; MDMA 2.5mg/kg, n=11; PIR 300 mg/kg, n=12; PIR+MET, n=12; PIR+MDMA, n=11) in the Open Field Test (Actitrack, Panlab, Spain). PIR given alone caused no significant changes in mouse locomotor/exploratory behaviour, whereas the same dose combined with either MET or MDMA significantly enhanced their stimulatory effects. Different possible neurobiological mechanism underlying drug-drug interaction of PIR with MET or MDMA are discussed, as modulation of dopaminergic, glutamatergic or cholinergic brain systems. However, the interaction with membrane phospholipids seems as the most plausible mechanism explaining PIR action on activities of neurotransmitter systems. Despite that our behavioural experiment cannot serve for explanation of the pharmacological mechanisms of these functional interactions, it shows that PIR effects can increase behavioural stimulation of amphetamine drugs. Thus, the reported combining of PIR with MET or MDMA by human abusers is not perhaps a coincidental phenomenon and may be based on existing PIR potential to intensify acute psychostimulant effects of these drugs of abuse.
- 650 _2
- $a amfetaminy $x aplikace a dávkování $7 D000662
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a chování zvířat $x účinky léků $x fyziologie $7 D001522
- 650 _2
- $a stimulanty centrálního nervového systému $x aplikace a dávkování $7 D000697
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a neuroprotektivní látky $x aplikace a dávkování $7 D018696
- 650 _2
- $a piracetam $x aplikace a dávkování $7 D010889
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Machalova, Alena
- 700 1_
- $a Landa, Leos
- 700 1_
- $a Vrskova, Dagmar
- 700 1_
- $a Sulcova, Alexandra
- 773 0_
- $w MED00003234 $t Medical hypotheses $x 1532-2777 $g Roč. 79, č. 2 (2012), s. 216-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22607774 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20130110114338 $b ABA008
- 999 __
- $a ok $b bmc $g 963584 $s 798966
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 79 $c 2 $d 216-8 $i 1532-2777 $m Medical hypotheses $n Med Hypotheses $x MED00003234
- LZP __
- $a Pubmed-20130108